Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Price Target of $15.40 According to Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have received an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $15.40.

DRTS has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, October 20th. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 1st. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Thursday, October 15th. Finally, Barclays boosted their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd.

Alpha Tau Medical Price Performance

Alpha Tau Medical stock opened at $13.72 on Monday. The stock’s 50 day moving average is $14.13 and its 200 day moving average is $10.75. Alpha Tau Medical has a one year low of $3.43 and a one year high of $15.79. The firm has a market cap of $1.24 billion, a P/E ratio of -13.19 and a beta of 1.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.09 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). As a group, research analysts expect that Alpha Tau Medical will post -1.05 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,352,700. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Everhart Financial Group Inc. acquired a new stake in Alpha Tau Medical during the second quarter worth approximately $126,000. Renaissance Technologies LLC bought a new position in shares of Alpha Tau Medical during the 1st quarter worth approximately $286,000. Finally, Principal Financial Group Inc. bought a new position in shares of Alpha Tau Medical during the 1st quarter worth approximately $132,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing targeted radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver highly localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses tiny radioactive sources, including radium-224, that are placed in or near a tumor. The sources generate short-range alpha-emitting atoms that diffuse through the tumor and damage cancer cells.